Big Pharma Voluntary List Price Reductions Doubtful, Sen. Warren Says
Executive Summary
Companies responding to inquiries from Sens. Elizabeth Warren, D-Mass., and Tina Smith, D-Minn., did not indicate they are planning to reduce list prices, despite promises by President Trump, Warren told a June 12 hearing.
You may also be interested in...
Merck's New Pricing Pledge Shows Style Over Substance
A 60% price reduction on hepatitis C drug Zepatier sounds impressive, but the drug has been declining and the HCV space overall is shrinking. Another set of 10% reductions come on small-sellers that are now generic.
Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump
After a conversation with President Trump, CEO Ian Read agreed to cancel price increases on 40 drugs that took effect July 1, to give the administration time to work on its blueprint for improving the health care system.
Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump
After a conversation with President Trump, CEO Ian Read agreed to cancel price increases on 40 drugs that took effect July 1, to give the administration time to work on its blueprint for improving the health care system.